The 9 most recent market catalysts affecting $SYRE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 26, 2026
Corporate Catalyst
Bearish
Impact 95
Spyre Therapeutics Says Rheumatoid Arthritis Program Misses Internal Benchmark, Stock Tumbles
Spyre Therapeutics (SYRE) reported topline results for its SPY072 rheumatoid arthritis (RA) program, indicating that while the drug showed statistical significance in improving sym…
Aug 26, 2026
Corporate Catalyst
Bearish
Impact 55
Wedbush Maintains Outperform on Spyre Therapeutics, Lowers Price Target to $123
Wedbush analyst David Nierengarten reiterated an 'Outperform' rating for Spyre Therapeutics, signaling continued confidence in the company's long-term prospects. However, the price…
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 65
BTIG Maintains Buy on Spyre Therapeutics, Raises Price Target to $132
BTIG analyst Julian Harrison has maintained a 'Buy' rating on Spyre Therapeutics (SYRE) and raised the price target from $112 to $132. This action signals increased confidence from…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Wells Fargo Maintains Overweight on Spyre Therapeutics, Raises Price Target to $115
Wells Fargo analyst Yanan Zhu has maintained an 'Overweight' rating on Spyre Therapeutics and raised the price target from $90 to $115. This indicates a stronger conviction from th…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Guggenheim Maintains Buy on Spyre Therapeutics, Raises Price Target to $130
Guggenheim analyst Yatin Suneja maintained a 'Buy' rating for Spyre Therapeutics and raised the price target from $115 to $130. This action signals increased confidence from a prom…
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 55
Wedbush Maintains Outperform on Spyre Therapeutics, Raises Price Target to $130
Wedbush analyst David Nierengarten has raised the price target for Spyre Therapeutics (SYRE) from $100 to $130 while maintaining an Outperform rating. This action signals increased…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 75
Spyre Therapeutics Q2 EPS $(0.36) Beats $(0.73) Estimate
Spyre Therapeutics (SYRE) announced Q2 losses of $(0.36) per share, significantly beating the analyst consensus estimate of $(0.73) by over 50%. This also represents a 26.53% impro…
Jul 28, 2026
Corporate Catalyst
Bearish
Impact 55
Wolfe Research Downgrades Spyre Therapeutics to Peer Perform
Wolfe Research, through analyst Andy Chen, has downgraded Spyre Therapeutics (SYRE) from an 'Outperform' rating to 'Peer Perform'. This matters because analyst ratings can influenc…
Jul 13, 2026
Corporate Catalyst
Bullish
Impact 65
Mizuho Maintains Outperform on Spyre Therapeutics, Raises Price Target to $120
Mizuho analyst Joseph Catanzaro has raised the price target for Spyre Therapeutics (SYRE) from $84 to $120, while maintaining an Outperform rating. This upward revision in the pric…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.